Callan Capital LLC Purchases 2,122 Shares of Johnson & Johnson (NYSE:JNJ)

Callan Capital LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 30.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,090 shares of the company's stock after buying an additional 2,122 shares during the quarter. Callan Capital LLC's holdings in Johnson & Johnson were worth $1,507,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its position in Johnson & Johnson by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock valued at $33,666,460,000 after purchasing an additional 1,772,706 shares during the last quarter. Geode Capital Management LLC raised its position in Johnson & Johnson by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock valued at $8,321,881,000 after purchasing an additional 1,561,036 shares during the last quarter. Northern Trust Corp raised its position in Johnson & Johnson by 12.3% in the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock valued at $4,456,201,000 after purchasing an additional 3,363,235 shares during the last quarter. Norges Bank bought a new position in Johnson & Johnson in the fourth quarter valued at about $4,390,037,000. Finally, Wellington Management Group LLP raised its position in Johnson & Johnson by 1.8% in the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock valued at $3,522,447,000 after purchasing an additional 431,205 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

JNJ has been the subject of several research reports. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Trading Up 0.3%

NYSE JNJ traded up $0.49 during trading hours on Tuesday, hitting $155.76. 6,432,336 shares of the company's stock were exchanged, compared to its average volume of 9,073,093. The stock has a 50-day simple moving average of $153.67 and a 200 day simple moving average of $154.24. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The firm has a market cap of $374.77 billion, a price-to-earnings ratio of 17.33, a PEG ratio of 2.36 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. On average, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.34%. Johnson & Johnson's payout ratio is currently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.